India COVID-19: As on Date: Total Number of Active Cases data was reported at 35.000 Case in 05 May 2025. This records an increase from the previous number of 29.000 Case for 28 Apr 2025. India COVID-19: As on Date: Total Number of Active Cases data is updated daily, averaging 44,029.000 Case from Mar 2020 (Median) to 05 May 2025, with 1587 observations. The data reached an all-time high of 3,745,237.000 Case in 10 May 2021 and a record low of 1.000 Case in 24 Feb 2025. India COVID-19: As on Date: Total Number of Active Cases data remains active status in CEIC and is reported by Ministry of Health and Family Welfare. The data is categorized under High Frequency Database’s Disease Outbreaks – Table IN.HLF006: Disease Outbreaks: Coronavirus 2019: MOHFW.

India COVID-19: As on Date: Total Number of Confirmed Cases data was reported at 45,044,752.000 Case in 28 Apr 2025. This records an increase from the previous number of 45,044,668.000 Case for 21 Apr 2025. India COVID-19: As on Date: Total Number of Confirmed Cases data is updated daily, averaging 43,124,585.500 Case from Mar 2020 (Median) to 28 Apr 2025, with 1586 observations. The data reached an all-time high of 45,044,752.000 Case in 28 Apr 2025 and a record low of 110.000 Case in 15 Mar 2020. India COVID-19: As on Date: Total Number of Confirmed Cases data remains active status in CEIC and is reported by Ministry of Health and Family Welfare. The data is categorized under High Frequency Database’s Disease Outbreaks – Table IN.HLF006: Disease Outbreaks: Coronavirus 2019: MOHFW.

As of January 1, 2025, the number of active coronavirus (COVID-19) infections in Italy was approximately 218,000. Among these, 42 infected individuals were being treated in intensive care units. Another 1,332 individuals infected with the coronavirus were hospitalized with symptoms, while approximately 217,000 thousand were in isolation at home. The total number of coronavirus cases in Italy reached over 26.9 million (including active cases, individuals who recovered, and individuals who died) as of the same date. The region mostly hit by the spread of the virus was Lombardy, which counted almost 4.4 million cases.For a global overview, visit Statista's webpage exclusively dedicated to coronavirus, its development, and its impact.

This dataset provides values for CORONAVIRUS DEATHS reported in several countries. The data includes current values, previous releases, historical highs and record lows, release frequency, reported unit and currency.

COVID-19 was first detected in Brazil on March 1, 2020, making it the first Latin American country to report a case of the novel coronavirus. Since then, the number of infections has risen drastically, reaching approximately 38 million cases by May 11, 2025. Meanwhile, the first local death due to the disease was reported in March 19, 2020. Four years later, the number of fatal cases had surpassed 700,000. The highest COVID-19 death toll in Latin America With a population of more than 211 million inhabitants as of 2023, Brazil is the most populated country in Latin America. This nation is also among the most affected by COVID-19 in number of deaths, not only within the Latin American region, but also worldwide, just behind the United States. These figures have raised a debate on how the Brazilian government has dealt with the pandemic. In fact, according to a study carried out in May 2021, more than half of Brazilians surveyed disapproved of the way in which former president Jair Bolsonaro had been dealing with the health crisis. In comparison, a third of respondents had a similar opinion about the Ministry of Health. Brazil’s COVID-19 vaccination campaign rollout Brazil’s vaccination campaign started at the beginning of 2021, when a nurse from São Paulo became the first person in the country to get vaccinated against the disease. A few years later, roughly 88 percent of the Brazilian population had received at least one vaccine dose, while around 81 percent had already completed the basic immunization scheme. With more than 485.2 million vaccines administered as of March 2023, Brazil was the fourth country with the most administered doses of the COVID-19 vaccine globally, after China, India, and the United States.Find the most up-to-date information about the coronavirus pandemic in the world under Statista’s COVID-19 facts and figures site.

India COVID-19: As on Date: Total Number of Cured/Discharged/Migrated data was reported at 44,511,086.000 Case in 05 May 2025. This records an increase from the previous number of 44,511,058.000 Case for 28 Apr 2025. India COVID-19: As on Date: Total Number of Cured/Discharged/Migrated data is updated daily, averaging 42,584,710.000 Case from Mar 2020 (Median) to 05 May 2025, with 1587 observations. The data reached an all-time high of 44,511,086.000 Case in 05 May 2025 and a record low of 13.000 Case in 16 Mar 2020. India COVID-19: As on Date: Total Number of Cured/Discharged/Migrated data remains active status in CEIC and is reported by Ministry of Health and Family Welfare. The data is categorized under High Frequency Database’s Disease Outbreaks – Table IN.HLF006: Disease Outbreaks: Coronavirus 2019: MOHFW.

COVID-19: As on Date: Number of Cured/Discharged/Migrated: Delhi data was reported at 2,017,021.000 Case in 05 May 2025. This records an increase from the previous number of 2,017,018.000 Case for 28 Apr 2025. COVID-19: As on Date: Number of Cured/Discharged/Migrated: Delhi data is updated daily, averaging 1,871,311.000 Case from Mar 2020 (Median) to 05 May 2025, with 1587 observations. The data reached an all-time high of 2,017,021.000 Case in 05 May 2025 and a record low of 2.000 Case in 18 Mar 2020. COVID-19: As on Date: Number of Cured/Discharged/Migrated: Delhi data remains active status in CEIC and is reported by Ministry of Health and Family Welfare. The data is categorized under High Frequency Database’s Disease Outbreaks – Table IN.HLF006: Disease Outbreaks: Coronavirus 2019: MOHFW.

The Asia Pacific COVID-19 diagnostics market is being aided by the growing cases of COVID-19 infections in India and China, which have performed around 234 million and 160 million tests, respectively, for COVID-19 as of March 2021.

COVID-19: As on Date: Number of Confirmed Cases: Gujarat data was reported at 1,292,774.000 Case in 05 May 2025. This records an increase from the previous number of 1,292,773.000 Case for 28 Apr 2025. COVID-19: As on Date: Number of Confirmed Cases: Gujarat data is updated daily, averaging 1,224,823.500 Case from Mar 2020 (Median) to 05 May 2025, with 1582 observations. The data reached an all-time high of 1,292,774.000 Case in 05 May 2025 and a record low of 5.000 Case in 20 Mar 2020. COVID-19: As on Date: Number of Confirmed Cases: Gujarat data remains active status in CEIC and is reported by Ministry of Health and Family Welfare. The data is categorized under High Frequency Database’s Disease Outbreaks – Table IN.HLF006: Disease Outbreaks: Coronavirus 2019: MOHFW.

Arbidol Tablets COVID-19 Sales Market Outlook

The Arbidol Tablets COVID-19 sales market size is experiencing significant growth, marked by a projected Compound Annual Growth Rate (CAGR) of 5.8% from 2024 to 2032. In 2023, the global market size for Arbidol Tablets was valued at approximately USD 750 million, and it is forecasted to reach USD 1.3 billion by 2032. This growth is primarily driven by the increasing demand for effective antiviral treatments amid ongoing concerns about COVID-19 and its variants. The continued emphasis on public health measures and the introduction of new formulations are key drivers contributing to the expansion of this market.

One of the pivotal growth factors for the Arbidol Tablets market is the sustained global focus on mitigating the impact of COVID-19. Arbidol, known for its antiviral properties, has been increasingly recognized as a supportive treatment for COVID-19, particularly in regions where healthcare systems are overburdened. The drug's potential to prevent viral replication and reduce the severity of symptoms has prompted its inclusion in treatment protocols in several countries. Additionally, the ongoing mutation of the coronavirus necessitates the availability of versatile and effective therapeutic options, further bolstering the demand for Arbidol Tablets. This has stimulated research and development efforts to enhance the drug's efficacy, ultimately driving market growth.

Another factor propelling the market is the strategic expansion of distribution channels. The accessibility of Arbidol Tablets through various pharmaceutical outlets such as hospital pharmacies, retail pharmacies, and online platforms ensures that patients have multiple avenues to procure the medication. The rise of e-commerce, especially during the pandemic, has made online pharmacies a popular choice for consumers seeking convenience and safety. This shift in consumer preference has prompted pharmaceutical companies to establish robust supply chains and logistical frameworks that cater to both traditional and digital sales channels, thereby increasing overall market penetration and sales volumes.

The increasing awareness regarding the benefits of Arbidol Tablets for both treatment and preventive purposes has also been a significant growth factor. Public health campaigns and information dissemination by health organizations have educated the public and healthcare providers about the drug's utility in managing COVID-19 symptoms and reducing the risk of infection. This has led to broader adoption among healthcare providers who are keen to incorporate effective antiviral agents into their treatment regimens. Furthermore, the positive outcomes from clinical studies and real-world evidence of the drug's efficacy have reinforced its reputation, encouraging its widespread use and contributing to market expansion.

In the realm of COVID-19 treatment, the role of Chemical Medication has been pivotal, especially with the emergence of new variants. Chemical Medication in COVID-19 has been instrumental in providing healthcare professionals with a variety of options to tailor treatment protocols according to patient needs. The development of chemical compounds that target specific viral mechanisms has enhanced the effectiveness of treatments like Arbidol, which is recognized for its antiviral properties. This has led to a broader understanding of how chemical medications can be optimized to combat the virus more efficiently, thereby improving patient outcomes. As research continues to advance, the integration of chemical medication into COVID-19 treatment regimens is expected to evolve, offering more precise and effective therapeutic solutions.

Regionally, the market outlook varies with Asia Pacific being the leading market in terms of Arbidol Tablets sales. The dense population and high prevalence of COVID-19 cases in countries like China and India have driven significant demand for antiviral treatments, including Arbidol. The presence of key manufacturers in the region also facilitates easy access to the medication. North America and Europe follow closely, with a growing emphasis on healthcare infrastructure development and investments in antiviral research. The Middle East & Africa and Latin America are also witnessing gradual growth as healthcare accessibility improves and awareness about Arbidol increases, although challenges such as regulatory hurdles and economic constraints persist in these regions.

Dosage Form Analysis

Camostat Mesylate Market Outlook

The global Camostat Mesylate market size was valued at approximately USD 450 million in 2023 and is expected to reach around USD 780 million by 2032, growing at a CAGR of about 6.5% during the forecast period from 2024 to 2032. This growth is driven by the increasing applications of Camostat Mesylate in treating various medical conditions, including its potential use in the management of COVID-19.

One of the primary growth factors for the Camostat Mesylate market is its efficacy in treating chronic pancreatitis. Pancreatitis is a condition marked by inflammation of the pancreas, which can lead to severe abdominal pain and digestive issues. Camostat Mesylate is an effective protease inhibitor that helps manage the symptoms of this condition, making it a crucial therapeutic option. The rising prevalence of pancreatitis globally, coupled with increased awareness among healthcare providers and patients, is significantly driving the demand for this drug.

Another significant growth driver for the Camostat Mesylate market is its emergent use in the treatment and management of COVID-19. During the COVID-19 pandemic, research indicated that Camostat Mesylate could potentially inhibit the activity of the virus, specifically the SARS-CoV-2 virus responsible for the disease. This led to a surge in demand as healthcare professionals and researchers sought effective treatments to combat the global pandemic. Although more clinical trials and studies are required to confirm its efficacy, the initial findings have fueled market growth.

The continuous development of pharmaceutical distribution channels also plays a critical role in the market's expansion. With the advent of online pharmacies and the increased accessibility of medications, patients now have more convenient options to obtain their prescriptions. This ease of access has significantly contributed to the market's growth, ensuring that patients receive timely and uninterrupted treatment. Additionally, traditional distribution channels like hospitals and clinics remain mainstays in ensuring that this essential medication reaches those in need.

From a regional perspective, the Asia Pacific region holds a substantial share of the Camostat Mesylate market due to the high prevalence of pancreatitis and increasing COVID-19 cases in countries like China and India. Additionally, the region benefits from significant investments in healthcare infrastructure and pharmaceutical R&D. North America and Europe also represent significant markets, driven by advanced healthcare systems, higher awareness, and substantial healthcare spending. The Middle East & Africa and Latin America regions exhibit moderate growth, with increasing healthcare initiatives and improving medical infrastructure contributing to the market expansion.

Product Type Analysis

The Camostat Mesylate market is segmented by product type, including tablets, injections, and other forms. Tablets represent one of the primary product types, widely favored for their convenience, ease of administration, and patient compliance. The tablet form of Camostat Mesylate is particularly popular in outpatient settings where long-term management of conditions like pancreatitis is required. The formulation of tablets ensures consistent dosage and ease of storage, which are critical factors for both patients and healthcare providers.

Injections, as another product type, are predominantly utilized in acute care settings. This form allows for rapid onset of action, making it suitable for conditions requiring immediate therapeutic intervention. In the context of COVID-19 treatment, injectable forms of Camostat Mesylate are being explored for their potential to deliver quick therapeutic benefits. The demand for injections is expected to rise as more clinical evidence supports their efficacy in managing acute symptoms associated with various conditions.

Other forms of Camostat Mesylate, which might include topical formulations or novel delivery systems, are also gaining attention in the market. These alternative forms are being developed to address specific clinical needs and improve patient outcomes. Innovations in drug delivery technologies could pave the way for new therapeutic applications, thereby expanding the market's reach. Research and development efforts are focused on enhancing the bioavailability and therapeutic efficacy of these alternative formulations.

Overall, the diversity in product types within the Camostat Mesylate market ensures that v

Cards And Payments Market Outlook

The global cards and payments market size was valued at approximately $10 trillion in 2023 and is projected to grow to around $15 trillion by 2032, exhibiting a compound annual growth rate (CAGR) of 4.5% over the forecast period. This impressive growth is primarily driven by the increasing digitization of financial services, greater consumer adoption of online and mobile payments, and expanding penetration of internet and smartphone usage across the globe.

One of the primary growth factors of the cards and payments market is the rapid advancement in technology, particularly in mobile and internet infrastructure. The proliferation of smartphones and the rising availability of high-speed internet have significantly influenced the adoption of digital payments. Consumers are increasingly relying on their mobile devices for everyday transactions, prompting businesses to adapt by offering various digital payment options. Additionally, the development of secure payment gateways and advanced encryption technologies has enhanced consumer trust in digital payment methods.

Another significant factor contributing to market growth is the shift in consumer behavior and preferences. The convenience and speed offered by online and mobile payments are unmatched, leading to a decline in cash transactions. The COVID-19 pandemic accelerated this trend by necessitating contactless payment methods to mitigate the spread of the virus. Consumers and businesses alike have become more comfortable with digital transactions, and this behavioral shift is expected to have a lasting impact on the market.

Regulatory support and government initiatives are also playing a crucial role in the expansion of the cards and payments market. Governments worldwide are promoting digital financial inclusion through various policies and programs aimed at increasing access to banking services. For instance, initiatives like India's Digital India campaign and the European Union's Revised Payment Services Directive (PSD2) have encouraged the adoption of digital payment methods, thereby boosting market growth.

Regionally, the Asia Pacific region is expected to witness the highest growth rate in the cards and payments market. This can be attributed to the rapid economic development, urbanization, and a large unbanked population that is gradually being brought into the formal banking system through digital means. Countries like China and India are at the forefront of this transformation, with significant investments in digital infrastructure and a burgeoning fintech ecosystem driving market growth.

Card Type Analysis

The cards and payments market is segmented into various card types, including credit cards, debit cards, prepaid cards, and others. Credit cards have traditionally been popular due to their credit facilities and reward programs. They allow consumers to borrow funds up to a certain limit and pay it back later, often with interest. The convenience of not needing to carry cash and the added benefits of rewards, cashback, and travel points have made credit cards a favored choice among consumers. Financial institutions continue to innovate with flexible repayment options and bonus point schemes to attract more users.

Debit cards, on the other hand, are directly linked to a consumer’s bank account and allow users to spend money they already have. They are widely accepted and offer immediate fund transfer without accruing debt. The simplicity and security associated with debit cards make them a popular choice for everyday transactions. With the rise of contactless payments, debit card usage has surged, as consumers appreciate the convenience of tapping their cards for swift transactions.

Prepaid cards offer another layer of flexibility and control for users. These cards are not linked to any bank account and are loaded with a specific amount of money. They are particularly useful for budgeting purposes or for specific use cases like travel or gifting. Prepaid cards also provide a safer alternative to carrying cash and can be used in places where credit or debit cards are accepted. The growing trend of digital wallets and e-gift cards is further propelling the demand for prepaid cards.

Other types of cards, including store cards and fleet cards, cater to niche markets but also contribute to the overall growth of the cards and payments market. Store cards are issued by specific retailers and offer rewards or discounts for purchases made at the issuing store. Fleet cards are used by b